Presented by Finance Advisors: Don’t invest alone. Take this 60-second quiz to connect with an advisor who can help you see your whole wealth picture. Get started here.
🔥 Good Morning from Top Tickers
Psychedelic Stock Surges 27% Before the Bell
A presidential executive order is the top story in premarket today.
One biotech name is surging on the news, while a multibillion-dollar acquisition is sending a building materials company sharply higher. Meanwhile, the AI chip race is evolving again, as a new custom silicon deal reshapes the competitive hierarchy among the industry’s biggest players.
The broader tape is under pressure from geopolitics.
Rising oil prices tied to renewed U.S.-Iran tensions are pulling down airlines, cruise lines, and consumer travel broadly. Crypto-linked names are nursing losses from a weekend bitcoin selloff. Gold and copper miners are slipping as the dollar strengthens and growth fears return to the fore.
🤝 Presented by Finance Advisors
Got Gains? Here’s What To Do Next.
Making money is one thing. Keeping it is another.
Without a plan, taxes, volatility, and bad decisions can undo your progress.
Take this short quiz, and we’ll match you with a vetted advisor who can help you:
Protect your profits
Grow your wealth smarter
Build a real financial plan
60-second quiz. Free call.
No pressure. Just clarity.
Prefer an ad-free read? Subscribe to Street Sheet Research.
🚀 Pre-Market Movers
The Biggest Gainers, Ranked
Compass Pathways (CMPS): +27%
Trump signed an executive order directing his administration to fast-track reviews of psychedelic drugs, and Compass Pathways landed squarely in the middle of it. The company has active clinical studies on psychedelic compounds for treatment-resistant depression and PTSD, precisely the conditions the order is designed to help.
TopBuild (BLD): +19%
QXO is acquiring the insulation installer and distributor for $17 billion. The buyer says the deal will improve margins and be immediately accretive to earnings, which is exactly the language that sends acquisition targets straight up premarket.
Marvell Technology (MRVL): +5%
Marvell is in talks with Google to build two new AI chips, according to a report from The Information. Landing Google as a custom chip customer would mark a meaningful expansion of Marvell's hyperscaler business, which has been the most reliable growth engine in semiconductors all year.
📉 Pre-Market Movers
The Biggest Losers, Ranked
AST SpaceMobile (ASTS): -12%
A satellite launched over the weekend ended up in the wrong orbit. The company says insurance should cover the loss, and its monthly-to-bimonthly launch cadence remains on track for 2026, but investors aren't waiting for reassurance.
American Airlines (AAL): -3%
Renewed U.S.-Iran tensions are raising fears about sustained elevated fuel costs and softer consumer demand for air travel. Delta Air Lines, United Airlines, and JetBlue Airways are all down, but American is leading the group lower.
Norwegian Cruise Line (NCLH): -2.5%
The same oil-price and consumer-demand fears hitting airlines are spilling into cruise lines. Carnival and Royal Caribbean Group are both off sharply as well, but Norwegian is taking the hardest hit in the group.
Strategy (MSTR): -2.5%
🤝 Presented by Finance Advisors
Trades Are Just One Part of the Equation
You’re getting Top Tickers, you’re trading smarter. But what’s your plan after you cash in?
Without a smart wealth strategy, gains can disappear faster than they grow. That’s why we’ve made it simple to connect with a trusted, vetted advisor who can help you:
Protect your profits from taxes and market swings
Build long-term wealth without the guesswork
Hit your financial goals faster with a tailored plan
This quiz only takes 30 seconds to get matched—and your first call is completely free, with zero obligation.
Make sure your wins today fuel your future success.
Prefer an ad-free read? Subscribe to Street Sheet Research.
👀 What We’re Watching
Here’s One Ticker That’s Trending Today
Definium Therapeutics (DFTX) + 16% (Pre-Market)
Trump's executive order on psychedelic drug reviews landed this weekend, and while Compass Pathways is getting the headline pop, some traders are looking past today and toward Wednesday.
Definium Therapeutics is hosting an Investor and Analyst Day in New York on April 22, where management is set to discuss the timeline for three Phase 3 clinical readouts expected later in 2026 for its lead compound, an LSD-based treatment for anxiety and depression.
The stock is moving higher before the market opens. Stifel recently initiated coverage with a Buy rating and a $30 price target. With the executive order providing sector tailwind and a high-profile management event two days out, this could set up as a pre-catalyst trade, or it could simply be a name that benefits from Compass Pathways' momentum and doesn't hold the gain. Either way, traders are watching it.
✌️That’s it for today.